06948nam 22013093u 450 991013961380332120220913234956.01-283-20363-497866132036320-470-92935-90-470-92934-0(CKB)2550000000042753(EBL)818637(OCoLC)746598445(SSID)ssj0000534041(PQKBManifestationID)12165841(PQKBTitleCode)TC0000534041(PQKBWorkID)10493413(PQKB)10894419(MiAaPQ)EBC818637(PPN)190360267(EXLCZ)99255000000004275320131230d2011|||| u|| |engur|n|---|||||txtccrAntiviral Drugs[electronic resource] From Basic Discovery Through Clinical TrialsHoboken Wiley20111 online resource (470 p.)Description based upon print version of record.1-118-25122-9 0-470-45563-2 ANTIVIRAL DRUGS; CONTENTS; CONTRIBUTORS; PREFACE; PART I HUMAN IMMUNODEFICIENCY VIRUS; 1 Discovery and Development of Atazanavir; 2 Discovery and Development of PL-100, A Novel HIV-1 Protease Inhibitor; 3 Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-Infected Patients; 4 Discovery and Development of Tipranavir; 5 TMC278 (Rilpivirine): A Next-Generation NNRTI in Phase III Clinical Development for Treatment-Naive Patients; 6 Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients7 Discovery and Development of Tenofovir Disoproxil Fumarate8 Discovery and Development of Apricitabine; 9 Discovery and Development of Maraviroc and PF-232798: CCR5 Antagonists for the Treatment of HIV-1 Infection; 10 Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the Treatment of HIV-1 Infection; 11 Discovery and Development of HIV-1 Entry Inhibitors That Target gp120; 12 Discovery of MK-0536: A Potential Second-Generation HIV-1 Integrase Strand Transfer Inhibitor with a High Genetic Barrier to Mutation; 13 Discovery and Development of HIV Integrase Inhibitor Raltegravir14 Elvitegravir: A Novel Monoketo Acid HIV-1 Integrase Strand Transfer InhibitorPART II HEPATITIS C VIRUS; 15 Discovery and Development of Telaprevir; 16 Discovery and Development of BILN 2061 and Follow-up BI 201335; 17 Intervention of Hepatitis C Replication Through NS3-4A, the Protease Inhibitor Boceprevir; 18 Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227); 19 Discovery and Development of the HCV Protease Inhibitor TMC435; 20 Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection21 Discovery and Development of PSI-6130/RG712822 Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV; 23 HCV Viral Entry Inhibitors; PART III RESPIRATORY SYNCYTIAL VIRUS INHIBITORS; 24 Discovery of the RSV Inhibitor TMC353121; 25 Discovery and Development of Orally Active RSV Fusion Inhibitors; 26 Discovery and Development of RSV604; PART IV INFLUENZA, HEPATITIS B, AND CYTOMEGALOVIRUS INHIBITORS; 27 Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza; 28 Discovery and Development of Entecavir29 Benzimidazole Ribonucleosides: Novel Drug Candidates for the Prevention and Treatment of Cytomegalovirus DiseasesINDEX; Color PlateThis book focuses on new small molecule approaches to combat viral infections. The chapters describe the discovery and development from bench through the clinic of relatively recently-approved antiviral drugs and compounds in advanced clinical development. Organized by a virus (such as HIV, HCV, RSV, influenza, HBV and CMV) and written by top academic and industrial authorities in the field, the book provides a unique opportunity to study, understand and apply discovery and development principles and learning without the need for an individual to research, analyze and synthesize all immense soAntiviral Agents -- therapeutic useAntiviral agentsClinical Trials as TopicDrug DiscoveryDrug EvaluationAntiviral agentsEpidemiologic StudiesChemistry, PharmaceuticalEvaluation Studies as TopicInvestigative TechniquesAnti-Infective AgentsEpidemiologic MethodsPharmacologyTherapeutic UsesHealth Care Evaluation MechanismsChemistryBiological Science DisciplinesNatural Science DisciplinesQuality of Health CarePublic HealthPharmacologic ActionsEnvironment and Public HealthHealth Care Quality, Access, and EvaluationChemical Actions and UsesHealth CareClinical Trials as TopicDrug DiscoveryAntiviral AgentsDrug EvaluationHealth & Biological SciencesHILCCPharmacy, Therapeutics, & PharmacologyHILCCAntiviral Agents -- therapeutic use.Antiviral agents.Clinical Trials as Topic.Drug Discovery.Drug Evaluation.Antiviral agentsEpidemiologic Studies.Chemistry, PharmaceuticalEvaluation Studies as TopicInvestigative TechniquesAnti-Infective AgentsEpidemiologic MethodsPharmacologyTherapeutic UsesHealth Care Evaluation MechanismsChemistryBiological Science DisciplinesNatural Science DisciplinesQuality of Health CarePublic HealthPharmacologic ActionsEnvironment and Public HealthHealth Care Quality, Access, and EvaluationChemical Actions and UsesHealth CareClinical Trials as TopicDrug DiscoveryAntiviral AgentsDrug EvaluationHealth & Biological SciencesPharmacy, Therapeutics, & Pharmacology615/.7924Kazmierski Wieslaw M859119Kazmierski Wieslaw MAU-PeELAU-PeELAU-PeELBOOK9910139613803321Antiviral Drugs1917539UNINA